Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma-Reference-Cited by-同舟云学术

Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma

Published:2020-06-30 Issue:1 Volume:20 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Ching Travers,Duncan Megan E.,Newman-Eerkes Tera,McWhorter Mollie M. E.,Tracy Jeffrey M.,Steen Michelle S.,Brown Ryan P.,Venkatasubbarao Srivatsa,Akers Nicholas K.,Vignali Marissa,Moorhead Martin E.,Watson Drew,Emerson Ryan O.,Mann Tobias P.,Cimler B. Melina,Swatkowski Pamela L.,Kirsch Ilan R.,Sang Charles,Robins Harlan S.,Howie Bryan,Sherwood Anna

Funder

Adaptive Biotechnologies Corporation

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-020-07077-9.pdf

Reference39 articles.

1. Bassan R, Bruggemann M, Radcliffe HS, Hartfield E, Kreuzbauer G, Wetten S. A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia. Haematologica. 2019;104(10):2028–39.

2. Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3(7):e170580.

3. Bruggemann M, Kotrova M. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. Hematology Am Soc Hematol Educ Program. 2017;2017(1):13–21.

4. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–60.

5. Health Quality O. Minimal residual disease evaluation in childhood acute lymphoblastic leukemia: a clinical evidence review. Ont Health Technol Assess Ser. 2016;16(7):1–52.

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL;Blood;2024-09-05

2. Long-Term Follow-Up of Patients With Follicular Lymphoma Using Next Generation Sequencing to Detect Minimal Residual Disease;Clinical Lymphoma Myeloma and Leukemia;2024-09

3. Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms;Blood Cancer Journal;2024-07-31

4. BertTCR: a Bert-based deep learning framework for predicting cancer-related immune status based on T cell receptor repertoire;Briefings in Bioinformatics;2024-07-25

5. How I use next-generation sequencing–MRD to plan approach and prevent relapse after HCT for children and adults with ALL;Blood;2024-07-18